Skip to main content

Stiolto Respimat FDA Approval History

FDA Approved: Yes (First approved May 21, 2015)
Brand name: Stiolto Respimat
Generic name: olodaterol and tiotropium
Dosage form: Inhalation Spray
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: COPD

Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).

Development timeline for Stiolto Respimat

DateArticle
May 26, 2015Approval FDA Approves Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for COPD
Aug 19, 2014Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol

See also

Stiolto Respimat (olodaterol and tiotropium) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer